View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorised
May 10, 2021

Coronavirus company news summary – Nicoya develops saliva-based rapid Covid-19 test – XPhyto begins pilot project to optimise rapid Covid-19 PCR test in Germany

By Chloe Kent

Nicoya Lifesciences is expected to complete the prototype of an affordable, single-use, self-administered Covid-19 test named Atlas, to detect active infection, mutant strains, and other viruses. The Atlas test uses a simple saliva collection kit and provides result in 20 minutes. Funded by the National Research Council of Canada (NRC), the company is developing the test together with the Public Health Agency of Canada (PHAC) as part of a joint challenge issued through the government’s Innovative Solutions Canada (ISC) programme.

XPhyto Therapeutics has initiated a pilot project with its rapid 25-minute Covid-19 PCR test, Covid-ID Lab, in a point-of-care setting in Germany. The pilot project includes mobile collection and PCR processing of the patient’s samples as well as testing of workflow logistics for further optimisation. The project is being undertaken in collaboration with Spitzweg Apotheke, a well-known German pharmacy.

At-home Covid-19 test kits have been made available over the counter in the St. Louis area. The different testing options include the Abbott BinaxNOW test, which is now available in CVS, Walgreens, and Walmart pharmacies, and Quidel QuickVue and Ellume, which will hit the stores in the coming weeks.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Medical Device Network